Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

MLH1 Promotor Hypermethylation in Colorectal and Endometrial Carcinomas from Patients with Lynch Syndrome

5 Dec 2023

Abstract excerpt

Screening for Lynch syndrome (LS) in colorectal cancer (CRC) and endometrial cancer patients generally involves immunohistochemical staining of the mismatch repair (MMR) proteins. In case of MLH1 protein loss, MLH1 promotor hypermethylation (MLH1-PM) testing is performed to indirectly distinguish the constitutional MLH1 variants from somatic epimutations. Recently, multiple studies have reported that MLH1-PM and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Genomics and Diagnostics
Share to Colorectal Cancer Screening and Detection
Share to Genetic factors in colorectal cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38061582
DOI: 10.1016/j.jmoldx.2023.10.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 24 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

MLH1 Promotor Hypermethylation in Colorectal and Endometrial Carcinomas from Patients with Lynch SyndromePMID 38061582Read ↗

MLH1 Promoter Methylation Could Be the Second Hit in Lynch Syndrome Carcinogenesis.Semantic proximity Read ↗

Lynch syndrome-associated endometrial carcinoma with MLH1 germline mutation and MLH1 promoter hypermethylation: a case report and literature reviewSemantic proximity Read ↗

MLH1/PMS2-deficient Endometrial Carcinomas in a Universally Screened Population: MLH1 Hypermethylation and Germline Mutation StatusSemantic proximity Read ↗

MLH1 methylation screening is effective in identifying epimutation carriers.Semantic proximity Read ↗

MLH1 promoter methylation frequency in colorectal cancer patients and related clinicopathological and molecular features.Semantic proximity Read ↗

Universal screening for Lynch syndrome in endometrial cancers: frequency of germline mutations and identification of patients with Lynch-like syndrome.Semantic proximity Read ↗

Testing region selection and prognostic analysis of MLH1 promoter methylation in colorectal cancer in ChinaSemantic proximity Read ↗

Clinical and genetic characterization of constitutional MLH1 promoter hypermethylation: Implications for Lynch syndrome diagnosis.Semantic proximity Read ↗

Clinicopathological and molecular characterization of Brazilian families at risk for Lynch syndrome.Semantic proximity Read ↗

Epidemiological, clinical and molecular characterization of Lynch‐like syndrome: A population‐based studySemantic proximity Read ↗

Tumour MLH1 promoter region methylation testing is an effective prescreen for Lynch Syndrome (HNPCC).Semantic proximity Read ↗

The MLH1 c.-27C>A and c.85G>T variants are linked to dominantly inherited MLH1 epimutation and are borne on a European ancestral haplotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.